EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sex-Specific Differences in Myocardial Injury Incidence after COVID-19 mRNA-1273 Booster Vaccination

Natacha Buergin iD, Pedro Lopez-Ayala, Julia R Hirsiger, Philip Mueller, Daniela Median, Noemi Glarner, Klara Rumora, Timon Herrmann, Luca Koechlin, Philip Haaf, Katharina Rentsch, Manuel Battegay und 3 weitere

European Journal of Heart Failure · 01.10.2023 · 25 (10) · 1871-1881

DOI: 10.1002/ejhf.2978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 09.08.2023. Verfasst von Natacha Buergin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: COVID-19, Heart Failure. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Basel and the University Hospital Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims To explore the incidence and potential mechanisms of oligosymptomatic myocardial injury following COVID-19 mRNA booster vaccination. Methods and results Hospital employees scheduled to undergo mRNA-1273 booster vaccination were assessed for mRNA-1273 vaccination-associated myocardial injury, defined as acute dynamic increase in high-sensitivity cardiac troponin T (hs-cTnT) concentration above the sex-specific upper limit of normal on day 3 (48–96 h) after vaccination without evidence of an alternative cause. To explore possible mechanisms, antibodies against interleukin-1 receptor antagonist (IL-1RA), the SARS-CoV-2-nucleoprotein (NP) and -spike (S1) proteins and an array of 14 inflammatory cytokines were quantified. Among 777 participants (median age 37 years, 69.5% women), 40 participants (5.1%; 95% confidence interval [CI] 3.7–7.0%) had elevated hs-cTnT concentration on day 3 and mRNA-1273 vaccine-associated myocardial injury was adjudicated in 22 participants (2.8% [95% CI 1.7–4.3%]). Twenty cases occurred in women (3.7% [95% CI 2.3–5.7%]), two in men (0.8% [95% CI 0.1–3.0%]). Hs-cTnT elevations were mild and only temporary. No patient had electrocardiographic changes, and none developed major adverse cardiac events within 30 days (0% [95% CI 0–0.4%]). In the overall booster cohort, hs-cTnT concentrations (day 3; median 5, interquartile range [IQR] 4–6 ng/L) were significantly higher compared to matched controls (n = 777, median 3 [IQR 3–5] ng/L, p < 0.001). Cases had comparable systemic reactogenicity, concentrations of anti-IL-1RA, anti-NP, anti-S1, and markers quantifying systemic inflammation, but lower concentrations of interferon (IFN)-λ1 (IL-29) and granulocyte-macrophage colony-stimulating factor (GM-CSF) versus persons without vaccine-associated myocardial injury. Conclusion mRNA-1273 vaccine-associated myocardial injury was more common than previously thought, being mild and transient, and more frequent in women versus men. The possible protective role of IFN-λ1 (IL-29) and GM-CSF warrant further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Heart FailureMaleHumansFemaleAdult2019-nCoV Vaccine mRNA-1273Granulocyte-Macrophage Colony-Stimulating FactorIncidenceSARS-CoV-2Vaccination

Stichwörter der Autor:innen

COVID-19COVID-19 booster vaccinationCardiac troponinMyocardial injuryMyocarditismRNA vaccine

Substanzen

2019-nCoV Vaccine mRNA-1273Granulocyte-Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Biomedicine, Translational Immunology, University of Basel, Basel, Switzerland.
  • Department of Laboratory Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Internal Medicine, Medical Outpatient Unit, University Hospital Basel, Basel, Switzerland.
  • Health Service, University Hospital Basel, Basel, Switzerland.

ORCID-Profile: Natacha Buergin

Förderung

  • University of Basel and the University Hospital Basel, Switzerland

Zitieren

APA

Buergin, N., Lopez-Ayala, P., Hirsiger, J. R., Mueller, P., Median, D., Glarner, N., Rumora, K., Herrmann, T., Koechlin, L., Haaf, P., Rentsch, K., Battegay, M., Banderet, F., Berger, C. T., & Mueller, C. (2023). Sex-Specific Differences in Myocardial Injury Incidence after COVID-19 mRNA-1273 Booster Vaccination. European Journal of Heart Failure, 25(10), 1871-1881. https://doi.org/10.1002/ejhf.2978

Vancouver

Buergin N, Lopez-Ayala P, Hirsiger JR, Mueller P, Median D, Glarner N, et al. Sex-Specific Differences in Myocardial Injury Incidence after COVID-19 mRNA-1273 Booster Vaccination. European Journal of Heart Failure. 2023;25(10):1871-1881. doi:10.1002/ejhf.2978

BibTeX
@article{Buergin2023,
  author = {Buergin, Natacha and Lopez-Ayala, Pedro and Hirsiger, Julia R and Mueller, Philip and Median, Daniela and Glarner, Noemi and Rumora, Klara and Herrmann, Timon and Koechlin, Luca and Haaf, Philip and Rentsch, Katharina and Battegay, Manuel and Banderet, Florian and Berger, Christoph T and Mueller, Christian},
  title = {Sex-Specific Differences in Myocardial Injury Incidence after COVID-19 mRNA-1273 Booster Vaccination},
  journal = {European Journal of Heart Failure},
  year = {2023},
  volume = {25},
  number = {10},
  pages = {1871--1881},
  doi = {10.1002/ejhf.2978}
}
Kostenlos starten →